Synairgen posts positive clinical trial data for SNG001

astrazeneca dl covid 19 messenger rna biotechnology pharma vaccine technology pandemic — mRNAAstraZeneca

Synairgen

4.70p

12:30 15/11/24

4.44%

0.20p

Shares of Synairgen caught a bid following the release of clinical trial results which appeared to show that its SNG001 formulation against Covid-19 might lower the risk of severe disease or death in the most at risk patients.

FTSE AIM All-Share

728.67

15:45 15/11/24

n/a

Pharmaceuticals & Biotechnology

19,259.77

15:45 15/11/24

-2.70%

-535.19

"The improvement in standard of care for COVID-19 means that most patients are currently discharged fairly rapidly from hospital; however, this further analysis shows that some patients struggle in their battle with the virus and show signs of respiratory compromise, with faster breathing rates and lower oxygen saturations, despite being on oxygen," said Tom Wilkinson, Chief Investigator of the SPRINTER trial and Professor of Respiratory Medicine, University of Southampton.

"For these higher-risk patients, there remains an urgent need for new treatment options, and this analysis suggests that SNG001 could be a potentially efficacious treatment option for them ."

Shares of Synairgen finished the session 31.09% higher att 35.0p.